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Human OGA binds substrates in a conserved peptide recognition groove
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Modiﬁcation of cellular proteins with O-GlcNAc (O-linked
N-acetylglucosamine) competes with protein phosphorylation
and regulates a plethora of cellular processes. O-GlcNAcylation
is orchestrated by two opposing enzymes, O-GlcNAc transferase
and OGA (O-GlcNAcase or β-N-acetylglucosaminidase), which
recognizetheirtargetproteinsviaasyetunidentiﬁedmechanisms.
In the present study, we uncovered the ﬁrst insights into the
mechanismofsubstraterecognitionbyhumanOGA.Thestructure
of a novel bacterial OGA orthologue reveals a putative substrate-
binding groove, conserved in metazoan OGAs. Guided by this
structure,conservedaminoacidsliningthisgrooveinhumanOGA
were mutated and the activity on three different substrate proteins
[TAB1 (transforming growth factor-β-activated protein kinase
1-binding protein 1), FoxO1 (forkhead box O1) and CREB
(cAMP-response-element-binding protein)] was tested in an
in vitro deglycosylation assay. The results provide the ﬁrst
evidence that human OGA may possess a substrate-recognition
mechanism that involves interactions with O-GlcNAcylated
proteins beyond the GlcNAc-binding site, with possible implica-
tions for differential regulation of cycling of O-GlcNAc on
different proteins.
Key words: β-N-acetylglucosaminidase, O-linked N-acetyl-
glucosamine (O-GlcNAc), peptide recognition groove, protein
glycosylation.
INTRODUCTION
The O-GlcNAc (O-linked N-acetylglucosamine) modiﬁcation
is a dynamic and reversible form of protein glycosylation
occurringonspeciﬁcserineandthreonineresiduesofintracellular
proteins [1,2]. Since the initial discovery of O-GlcNAc [3],
technological advances have greatly facilitated its detection, and
proteomics studies [4–6] have shown that a signiﬁcant proportion
of cellular proteins are O-GlcNAcylated. However, the functional
importance of O-GlcNAc is only just emerging, with evidence to
suggestthatitmayregulateproteinactivityinamanneranalogous
(and complementary) to phosphorylation [7]. O-GlcNAc levels
are known to respond dynamically to nutrient availability [1]
and stress [8], and to undergo changes during the cell cycle
[9] and development [10]. O-GlcNAc has been shown to be
associatedwitharangeofhumandiseases[2].Strikingly,onlytwo
enzymes orchestrate the O-GlcNAc modiﬁcation. Both the OGT
(O-GlcNAc transferase)andits antagonisticOGA(O-GlcNAcase
or β-N-acetylglucosaminidase) are encoded by single genes in
metazoa [11,12]. Little is known about the mode of substrate
recognition of either enzyme, although studies have hinted at
the existence of a deﬁned O-GlcNAc peptide sequon [2,5]. In
addition, it is thought that, for a single OGT to modify speciﬁc
sites on a multitude of proteins, interactions with adapter proteins
may be instrumental in achieving selectivity and regulation of
activity [13].
OGA was ﬁrst identiﬁed as a neutral-pH hexosaminidase,
which was later associated with the gene MGEA5 (meningioma-
expressedantigen5)[14].ThedomainstructureofhOGA(human
OGA) is frequently oversimpliﬁed by designating an N-terminal
hexosaminidase followed by a C-terminal domain with sequence
homology with HATs (histone acetyltransferases) (referred to as
the HAT domain in the present paper). A further putative domain
may exist in the stretch of over 300 amino acids in between
the hexosaminidase and HAT domains. hOGA (Ser
405) is itself a
substrate for OGT [15]. Residues 404–548 have been shown to
be required for interaction with OGT [16], and it is thought that
the formation of such a complex negatively regulates O-GlcNAc
removal.
PharmacologicalinhibitionofOGAhasbeenaninvaluabletool
for investigating the cellular functions of O-GlcNAc; notably the
non-selective inhibitor PUGNAc [O-(2-acetamido-2-deoxy-D-
glucopyranosylidene)amino-N-phenylcarbamate] has been used
extensively to raise cellular O-GlcNAc levels [17]. Advances
in understanding of the OGA reaction mechanism [18], in
conjunction with structures of bacterial OGAs [19,20], have
informed the development of a number of highly potent and
selective inhibitors for hOGA [21].
Despite these recent advances in our understanding of OGA
structure, mechanism and inhibition, we do not understand
how OGA interacts with the protein part of its substrates.
Such interactions could constitute the basis of substrate
speciﬁcity in hOGA. In the present paper, we reveal that
hOGA possesses a conserved substrate-binding groove that
is required for the interaction with O-GlcNAc proteins.
Different substrates require distinct surface residues for binding,
affording a ﬁrst glimpse into the substrate selectivity of human
O-GlcNAcase.
Abbreviations used: CpNagJ, Clostridium perfringens NagJ; CREB, cAMP-response-element-binding protein; Fmoc, ﬂuoren-9-ylmethoxycarbonyl;
FoxO1, forkhead box O1; GST, glutathione transferase; HAT, histone acetyltransferase; HEK, human embryonic kidney; LC, liquid chromatography; 4MU-
GlcNAc, 4-methylumbelliferyl-β-N-acetylglucosamine; OGA, O-GlcNAcase or β-N-acetylglucosaminidase; hOGA, human OGA; OgOGA, Oceanicola
granulosus OGA; OGT, O-GlcNAc transferase; O-GlcNAc, O-linked N-acetylglucosamine; pNP-GlcNAc, p-nitrophenyl-β-N-acetylglucosamine; PUGNAc,
O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate; RMSD, root mean square deviation; TAB1, transforming growth factor-β-
activated protein kinase 1-binding protein 1.
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Structures have been deposited in the PDB under accession codes 2XSA and 2XSB.
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MATERIALS AND METHODS
Cloning, expression and structure determination of OgOGA
(Oceanicola granulosus OGA)
The O. granulosus gene for hyaluronoglucosaminidase
(ZP_01156836.1) was cloned from genomic DNA into pGEX6-
P1 for expression as a GST (glutathione transferase) fusion
in Escherichia coli. The protein OgOGA was puriﬁed by
afﬁnity, anion-exchange and size-exclusion chromatography
(see the Supplementary material at http://www.BiochemJ.
org/bj/432/bj4320001add.htm). OgOGA was crystallized at
1.9 mg/ml from PEG [poly(ethylene glycol)]/MgCl2 solutions
(see the Supplementary Online Data). The structure of the apo-
enzyme was solved using MAD (multiwavelength anomalous
diffraction) phasing with a lead derivative and the structure of
a PUGNAc complex was obtained by molecular replacement.
Diffraction data and model statistics are shown in Supplementary
Table S1 at http://www.BiochemJ.org/bj/432/bj4320001add.htm.
Glycopeptide synthesis and detection
A 3,4,6-triacetyl-O-GlcNAc-Fmoc (ﬂuoren-9-ylmethoxycarbon-
yl)-Ser-OH derivative was synthesized as described previously
[22]. Microwave-assisted solid-phase peptide synthesis was
performed with a CEM Liberty instrument on low-load
Rink amide MBHA (methylbenzhydrylamine) resin 100–200
mesh (Novabiochem) using standard Fmoc chemistry protocols
on a 0.05 mmol scale. The structural homogeneity of the
glycopeptides was veriﬁed by high-resolution mass spectra
taken on Bruker micro-TOF (time-of-ﬂight) instrument in
the direct injection mode. The same instrument was used for the
monitoring of the enzymatic deglycosylation in the LC (liquid
chromatography)–MS mode using an Agilent 1200 binary
analytical HPLC system equipped with a Waters X-Bridge C18
3 μm particles, 3.2 mm×50 mm column and diode array UV–
visible detector. Typically, the reaction was diluted to 0.3 ml
with water, then passed through a 10 kDa molecular-mass cut-
off concentrator to remove protein. Then, 10 μlo ft h eﬂ o w -
through was taken for the analysis using gradient elution (ﬂow
rate 0.3 ml/min) with a 5–95% linear gradient of acetonitrile
(0.1% ammonia) in water (0.1% ammonia).
hOGA cloning and expression
The coding sequence for full-length hOGA was cloned into the
pEBG-6Pvector[23]fortransientexpressioninmammaliancells.
Point mutations were introduced by site-directed mutagenesis
(see Supplementary Table S2 at http://www.BiochemJ.
org/bj/432/bj4320001add.htm for primers). The enzyme was
expressed as an N-terminal GST fusion in HEK (human
embryonic kidney)-293 cells cultivated in suspension. For
transfection, 2×10
8 HEK-293 cells were serum-deprived for 4 h
in 100 ml of Pro293sCDM medium before the addition of 10 ml
of serum-free medium containing 100 μg of plasmid DNA and
600 μg of polyethylenimine. After another 4 h, the cells were
diluted to 10
6 cells/ml, and the medium was supplemented with
1% (v/v) fetal bovine serum. Cell pellets were harvested 72 h
aftertransfectionandlysedin50 mMTris/HCl (pH 7.5),270 mM
sucrose, 0.1% 2-mercaptoethanol, 1 mM sodium orthovanadate,
1 mMEDTA,1 mMEGTA,5 mMpyrophosphate,10 mMsodium
2-glycerophosphate, 50 mM NaF, 1% Triton X-100, 1 mM
benzamidine, 0.2 mM PMSF and 5 μM leupeptin. GST–hOGA
was puriﬁed from cleared lysate by pull-down with glutathione–
Sepharose (GE Healthcare), followed by elution with 25 mM
reduced glutathione in 25 mM Tris/HCl buffer (pH adjusted to
7.5).
Colorimetric and ﬂuorimetric OGA assays
Initial rates of hydrolysis of pNP-GlcNAc (p-nitrophenyl-β-N-
acetylglucosamine) were measured in buffer containing 25 mM
Tris/HCl (pH 7.5) and 0.1 mg/ml BSA, with substrate concen-
trations ranging from 0 to 10 mM with a DMSO concentration of
2% throughout the assay. Reactions were performed with 5 nM
enzyme in a 50 μl assay volume. After 30 min of incubation
at 37◦C, the reaction was stopped by addition of 100 μlo f
3 M glycine/NaOH (pH 10.3), and product concentration was
measured at A405. 4MU-GlcNAc (4-methylumbelliferyl-β-N-
acetylglucosamine) assays were performed in the same buffer,
with substrate concentrations ranging from 0 to 8 mM, and the
enzyme concentration was reduced to 0.2 nM and the assay time
to 20 min. Product formation was determined ﬂuorimetrically
(λex =360 nm/λem =460 nm). Inhibition constants for OGA
inhibitors were obtained with 4MU-GlcNAc with substrate
concentrations equivalent to the Km. All experiments were
performed in triplicate, and results were analysed and plotted
using GraphPad Prism.
Kinetic parameters of 4MU-GlcNAc turnover by wild-type
and mutant hOGA were determined as described above, with
enzyme concentrations of 20 nM and a maximum substrate
concentration of 2 mM (1% DMSO in the assay). Competition
assays with peptides were performed at 200 μM4 M U -
GlcNAc. Km determination for GlcNAc-modiﬁed peptides was
performed following an approach using established equations for
multisubstrate enzyme kinetics to derive kinetic constants of a
substrate whose turnover cannot be detected directly [24]. The
ﬂuorigenic reporter substrate and the GlcNAcylated peptide are
consideredascompetitiveinhibitorsofeachother.Fromtheinitial
hydrolysis rates of 4MU-GlcNAc in the presence and absence of
the peptide, the Michaelis constant for the peptide (Km
 ) can be
determined from eqn (1):
vi
v0
=
1 +
Km
S
1 +
Km
S

1 +
S
 
Km
 
 (1)
where vi/v0 is the relative activity in the presence of inhibitor, Km
and S are the Michaelis constant and substrate concentration of
the reporter substrate respectively, and S
  is the concentration
of the peptide.
Determination of hOGA in vitro activity on O-GlcNAc proteins
The known O-GlcNAc targets FoxO1 (forkhead box O1) [25,26]
and CREB (cAMP-response-element-binding protein) [27] were
provided by the Division of Signal Transduction and Therapy,
UniversityofDundee,Dundee,Scotland,U.K.Botharetruncated
constructs and N-terminal GST-fusion proteins, GST–CREB-(1–
283), and GST–FoxO1-(329–655). A GST-fusion of the TAB1
(transforming growth factor-β-activated protein kinase 1-binding
protein1)N-terminaldomainandfull-lengthhOGTwerepuriﬁed
as described elsewhere [27a]. A truncated construct lacking
the ﬁrst nine TPRs (tetratricopeptide repeats) ( 9-hOGT) was
expressed in E. coli.
For GlcNAcylation reactions, target proteins were incubated
with 3.75 mM UDP-GlcNAc and recombinant OGT in 50 mM
Tris/HCl (pH 7.5) containing 1 mM DTT (dithiothreitol).
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Figure 1 Activity of hOGA and OgOGA
(A) The O-GlcNAc substrate proteins (10 μM) TAB1, FoxO1 and were subjected to in vitro GlcNAcylation by recombinant OGT (see Supplementary Figure S1 at
http://www.BiochemJ.org/bj/432/bj4320001add.htm). For the activity assay, these substrates, as well as GlcNAc-modiﬁed hOGA D175N, were incubated with hOGA (1 μM) at 37◦C, which
led to complete deglycosylation within 6 h as detected by anti-O-GlcNAc antibody. The top panel shows the enzyme hOGA as detected through its GST tag, the middle panel shows O-GlcNAcylation
using CTD110.6 anti-O-GlcNAc antibody, and the bottom panel shows all the substrate proteins through their GST tags (shorter exposure). (B) Competition of O-GlcNAc-modiﬁed peptides (tri-,
penta-,hepta-andnona-peptidesbasedontheO-GlcNAcsiteonhOGASer405)with4MU-GlcNActurnoverbyhOGAaffordsanestimateoftheafﬁnityofhOGAforthepeptidesubstrates(Table1).(C)
Mass spectrum showing the deglycosylation of Val-Ala-His-Ser-(β-O-GlcNAc)-Gly-Ala (molecular mass of 785 Da) to the deglycosylated form (molecular mass of 582 Da), also see Supplementary
Figure S2 at http://www.BiochemJ.org/bj/432/bj4320001add.htm.
Enzyme/substrate protein ratios were 1:20, total protein
concentration was 0.5 mg/ml. The reaction was allowed to
proceed for 3 h at 37◦C (see Supplementary Figure S1
at http://www.BiochemJ.org/bj/432/bj4320001add.htm). Full-
length hOGT was used to O-GlcNAcylate CREB and hOGA,
whereas the truncated  9-hOGT was used for FoxO1 and TAB1.
After the glycosylation reaction, target proteins were repuriﬁed
by GST pull-down, eluted in 25 mM Tris/HCl buffer (pH 7.5)
containing 25 mM reduced glutathione and spin-concentrated to
approx. 5 mg/ml.
In vitro removal of O-GlcNAc was performed in a 5 μl volume
in 25 mM Tris/HCl and 25 mM GST (pH 7.5), and contained
10 μM O-GlcNAcylated substrate protein and 1 μM wild-type
or mutant hOGA. Reaction mixtures were incubated for 4–6 h
at 37◦C, and a 1 μl aliquot was blotted for O-GlcNAc with
CTD110.6 (Abcam). DM-17 rabbit anti-hOGT antibody was
purchased from Sigma. GST and TAB1 antisera were obtained
from the Division of Signal Transduction and Therapy [28].
RESULTS AND DISCUSSION
Recombinant hOGA is active on O-GlcNAc-modiﬁed proteins and
peptides in vitro
Although hOGA has been shown to be active on a GlcNAc-
modiﬁed peptide substrate [29], most studies have been restricted
to measuring the enzyme activity in vitro using pseudosubstrates,
or monitoring OGA activity in vivo by Western blot analysis
of cellular O-GlcNAc levels after overexpression, knock down
or inhibition of OGA. We aimed to demonstrate in vitro
activity of hOGA on recombinant glycoproteins. Substrates were
prepared by in vitro glycosylation of the previously characterized
O-GlcNAc proteins TAB1 and the transcription factors FoxO1
andCREB(seeSupplementaryFigureS1).OGAassayswerethen
Table 1 Michaelis constants of O-GlcNAc-modiﬁed peptides for hOGA
Km values for peptides derived from the O-GlcNAc sites of two known substrate proteins were
determinedinacompetitiveassaywiththeﬂuorigenicsubstrate4MU-GlcNAc.Ac,acetyl;amino
acids in peptides are indicated using the single-letter code.
Substrate Km
hOGA-Ser405-derived peptide series
Ac-HS(-β-O-GlcNAc)G-NH2 525+ −13 μM
Ac-VAHS(-β-O-GlcNAc)GA-NH2 1204+ −43 μM
Ac-VAHS(-β-O-GlcNAc)GAK-NH2 789+ −36 μM
Ac-QVAHS(-β-O-GlcNAc)GAKAS-NH2 528+ −15 μM
TAB1-Ser395-derived peptide series:
Ac-YS(-β-O-GlcNAc)S-NH2 2.2+ −0.1 mM
Ac-PYS(-β-O-GlcNAc)SA-NH2 6.3+ −0.5 mM
Ac-VPYS(-β-O-GlcNAc)SAQ-NH2 4.1+ −0.3 mM
Ac-SVPYS(-β-O-GlcNAc)SAQS-NH2 4.8+ −0.3 mM
performed with these substrates as well as a glycosylated hOGA-
inactivemutant,andreductionofO-GlcNAcwasdetectedbyanti-
O-GlcNAc Western blot analysis, showing that hOGA is capable
of removing O-GlcNAc from these glycoproteins (Figure 1A).
We next sought to identify peptide substrates that would allow
the determination of the Michaelis constant (Km), and also allow
for varying sequence and length to probe substrate speciﬁcity.
Peptides covered the O-GlcNAc sites on TAB1 (Ser
395)( S .P a t h a k
and D.M.F. van Aalten, unpublished work) and hOGA (Ser
405)[ 4 ]
(Table1).hOGAactivityonthesepeptideswasconﬁrmedbyLC–
MS. The afﬁnity of hOGA for these peptides was then quantiﬁed
by their ability to compete with the reporter substrate 4MU-
GlcNAc (Figure 1B and Table 1). The resulting Km values for the
hOGA-Ser
405-a n dT A B 1 - S e r
395-derived peptides are in the high-
micromolar and low-millimolar range respectively, somewhat
decreasing in afﬁnity with increasing peptide length.
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Discovery of a bacterial OGA with improved similarity to the human
enzyme
hOGA is known to possess an N-terminal catalytic domain
(residues 60–366) and the C-terminal HAT domain (residues
707–916) (Figure 2A). However, sequence analysis of putative
metazoan OGAs shows that they also possess a low-complexity
N-terminus(residues1–59),anda‘middle’domain(residues367–
707), also containing a low-complexity region (residues 396–
553). Only the catalytic domain is represented in the available
(bacterial) OGA structures, yet any of the additional hOGA
domains could contribute to substrate recognition/speciﬁcity.
In the absence of a hOGA structure to guide our substrate-
speciﬁcity studies, we aimed to identify new bacterial OGAs
with improved sequence identity and extending to beyond just the
catalytic domain. A BLAST search identiﬁed a predicted protein
from O. granulosus (OgOGA) that not only shows improved
sequenceidentity(37%)withthehOGAcatalyticdomainwithout
anyalignmentgaps(Figure2B),butalso,intriguingly,possessesa
200-residue C-terminal domain that shares approx. 20% identity
with the hOGA middle domain (Figures 2A and 2B). An OgOGA
structure would reveal the position of this domain with respect
to the active site and serve as a guide to identifying residues or
domains involved in glycoprotein substrate recognition.
To investigate the possible OGA activity of OgOGA, the
gene was cloned from genomic DNA and expressed in E. coli.
The enzyme shows OGA activity with pNP-GlcNAc (Km =
8.5+ −0.6 mM, kcat =24.0+ −1.0 s
−1) and 4MU-GlcNAc
(Km =2.9+ −0.2 mM, kcat =8.2+ −0.3 s
−1), with a pH optimum of
7.4–7.6(seeSupplementaryFigureS2Bathttp://www.BiochemJ.
org/bj/432/bj4320001add.htm). OgOGA is sensitive to the
commonly used OGA inhibitors PUGNAc (IC50 =11 μM) and
GlcNAcstatin G [29a] (IC50 =780 nM). OgOGA was also able to
quantitatively deglycosylate a glycopentapeptide, Val-Ala-His-
Ser-(β-O-GlcNAc)-Gly-Ala, derived from the reported hOGA
O-GlcNAc site [4], as detected by LC–MS (Figure 1C and
Supplementary Figure S2).
OgOGA possesses a conserved peptide-binding groove and ‘stalk’
We next explored the structural similarities of OgOGA with
hOGA to allow exploitation of OgOGA as a structural guide
for hOGA mutagenesis studies. OgOGA was crystallized and
its structure solved, including a complex with PUGNAc (see
Supplementary Table S1). The OgOGA structure reveals an
N-terminalTIMbarreldomainandaC-terminalα-helicaldomain
(Figures 2A and 2C). The OgOGA catalytic domain is similar to
that of CpNagJ (Clostridium perfringens NagJ) [RMSD (root
mean square deviation)=1.5 Å (1 Å=0.1 nm) for 254 Cαs;
Figure 2C]. The α4–β5, β3–α3, β4–α4a n dβ5–α5 loops are of
differentlengthsand/oradoptdifferentconformations.Strikingly,
sequence alignments show that these loops match hOGA, but
not CpNagJ, in length and conservation (Figure 2B). The
C-terminal domain, hereafter referred to as the stalk domain,
possesses good sequence similarity with hOGA (Figure 2B) and
contains a core four-helical bundle (Figure 2C). Unexpectedly,
this domain is structurally similar to the third domain of CpNagJ
(RMSD=1.9 Å for 110 Cαs, yet <10% sequence identity;
Figure 2C), although the loops connecting the helices differ
in length and conformation. In particular, the α10–α11 loop is
nine residues longer in CpNagJ compared with OgOGA (and, by
alignment, hOGA; Figure 2B), reaching into the CpNagJ active
site,whichisimpossibleinOgOGA(andthusunlikelyinhOGA).
Similarly, the OgOGA structure suggests structural homology
between the stalk domain of Bacteroides thetaiotaomicron
OGA [20] and hOGA (see Supplementary Figure S3 at
http://www.BiochemJ.org/bj/432/bj4320001add.htm).
The OgOGA active site is formed by the TIM barrel β–α
loops (Figure 2C), with the catalytic loop residues Asp
115/Asp
116
on β4–α4 conserved with hOGA, compatible with the observed
OGA activity (Figure 2C). This loop does not fully engage with
the PUGNAc inhibitor, presumably related to the disordered
phenylcarbamate group. Ligand-induced conformational changes
in the β4–α4 loop have also been observed for CpNagJ [30].
Upon PUGNAc binding to OgOGA, the β7–η1 loop shifts by
up to 4.7 Å exposing the GlcNAc-binding site, associated with
smalldisplacementsoftheneighbouringβ8–α8andβ1–α1loops.
Residueshydrogen-bondingwiththesugarhydroxygroups(Gly
8,
Tyr
160,A s p
226 and Asn
254)o rt h eN-acetyl moiety (Asn
221)a r e
conserved in hOGA (Figures 2B and 2E). Similarly, the residues
that show van der Waals/stacking interactions with the sugar and
the N-acetyl group (Tyr
10,T y r
160 and Trp
219) are conserved in
hOGA. Strikingly, the surface around the active site, together
with the stalk domain, forms a groove lined by side chains that
are highly conserved/identical between OgOGA and hOGA and
also among metazoan OGAs (Figure 2D).
Residues lining the conserved binding groove are required
for hOGA–substrate interactions
Wenexttestedthehypothesisthattheconservedgrooverepresents
the binding site for O-GlcNAc glycoprotein substrates by
expressing GST-fusions of 20 individual hOGA point mutants
of residues lining the groove (Figures 2B and 2D). To control
for effects on protein folding and/or catalysis rather than protein
substrate binding, we measured 4MU-GlcNAc hydrolysis by
these mutants (Figure 3A). Mutations affecting 4MU-GlcNAc
hydrolysis are mostly located close to the sugar/catalytic
machinery (Tyr
69) or occupy positions shown to undergo a
conformational change upon inhibitor binding (Tyr
286 and Asp
287
in the β7–η1 loop) (Figure 2). Strikingly, de-O-GlcNAcylation
assays with the TAB1, FoxO1 and CREB glycoprotein substrates
identiﬁed mutants of residues some distance from the active site
(I176L, S190A, S190Q, T217A, E218S, F223S and K289A) with
reduced activity against one or more of the protein substrates, yet
unimpaired 4MU-GlcNAc hydrolysis (Figure 3).
Conclusions
Since its discovery more than three decades ago, it has
become clear that O-GlcNAc is an important post-translational
modiﬁcation found on hundreds of intracellular proteins and
plays a role in signalling pathways. However, it is not clear
what determines speciﬁcity in the targeting and cycling of
O-GlcNAc on these proteins. We have investigated whether
OGA speciﬁcally recognizes the peptide component of its
glycoprotein substrates. Our ﬁndings show that, by similarity
to the structurally related bacterial OgOGA, hOGA possesses a
putative substrate-binding groove that is highly conserved within
metazoan OGAs, in addition to a stalk domain in close proximity
totheactivesite.Indeed,mutationstargetingthisgrooveidentiﬁed
residues that are not required for hydrolysis of the 4MU-
GlcNAc pseudosubstrate, but affected hydrolysis of glycoprotein
substrates. Although a limited set of glycoprotein substrates
(TAB1, FoxO1 and CREB) and peptides (derived from TAB1
and hOGA itself) was tested, these mutational studies hinted at
differential substrate recognition. The differences between the
residues required for the turnover of these substrates may reﬂect
differences in the molecular environment of the O-GlcNAc site(s)
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Figure 2 Structure of OgOGA and similarity to other OGAs
(A)DomainarchitectureofhumanOGA.Predictedordereddomainsareshownascolouredboxes(cyan,catalyticdomain;purple,stalkdomain;orange,HATdomain),predicteddisorderedregionsare
indicated by red wavy lines. (B) Sequence alignment of OgOGA and hOGA. Secondary-structure elements from the OgOGA structure are shown (red, α-helices; blue, β-strands; yellow, 310-helices),
broken lines denote residues disordered in apo-OgOGA. The proposed domains are indicated by boxes coloured as in (A). (C) Cartoon view of the OgOGA apo structure and domains 2 and 3 of
CpNagJ. (D) Surface view of OgOGA shaded by sequence conservation among metazoan OGAs (light blue) and metazoan OGAs+OgOGA (dark blue). The PUGNAc (green) complex is shown with
additional ordered loops taken from the apo-structure. (E) Active sites of the OgOGA–PUGNAc and CpNagJ–GlcNAcstatin complexes. The ligands are represented as sticks with green carbons, an
unbiased Fo −Fc;ϕc map (2.3 σ) is shown for PUGNAc. Hydrogen bonds are drawn as black broken lines. Hydrogen bonds to/from protein backbone amides are shown as originating from the Cα.
Active-site residues in OgOGA are labelled in black, alongside the equivalent hOGA residues in blue.
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Figure 3 Activity of hOGA groove mutants
Twenty individual mutants of hOGA were generated based on the structural information obtained from OgOGA. (A) To evaluate the structural integrity of the hOGA mutants, the catalytic efﬁciency
of 4MU-GlcNAc turnover was determined and compared with the wild-type (kcat/Km =7000 M−1·s−1) and the catalytically impaired D175N mutant (negative control). hOGA mutants were also
incubated with O-GlcNAc substrate proteins TAB1, FoxO1 and CREB, and deglycosylation was observed by Western blotting. (B) Visualization of the correlation between the mutants’ ability to
hydrolyse the pseudosubstrate 4MU-GlcNAc and glycoprotein substrates. Catalytically impaired mutants (kcat/Km for 4MU-GlcNAc 50% of wild-type) locate in the areas shaded in red. Mutants
unaffected inboth4MU-GlcNActurnoverandproteindeglycosylation(cut-off10%reductionofwild-typeactivity) areshownin theblueareas.MutationsreducingOGAactivity onproteinsubstrates
only are depicted in the yellow areas. Location of the mutations is shown on the surface around the active site of OgOGA (coloured by domain, see Figure 2A). The mutated amino acids are shaded
according to correlation plots, thus amino acids affecting protein substrate recognition are highlighted in yellow.
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on these proteins/peptides, and could tune O-GlcNAc cycling
rates. Together, the results of the present study constitute the ﬁrst
evidenceforspeciﬁcinteractionsbetweenhOGAanditssubstrate
proteins beyond the sugar moiety, and may form the basis of an
improved understanding of the enzyme’s substrate speciﬁcity and
the functional implications thereof.
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SUPPLEMENTARY MATERIALS AND METHODS
OgOGA cloning and expression
O. granulosus HTCC 2516 was obtained from the A.T.C.C.
(Manassas, VA, U.S.A.) (BAA-861) and grown at 30◦C over-
night in Difco marine agar/broth 2216. O. granulosus genomic
DNA was prepared following the method of Wilson [1]. The
full-length predicted OgOGA gene (protein accession number
ZP_01156836.1) was then ampliﬁed by PCR using the forward
primer 5
 -TTATGGATCCATGCTGACCGGGGTGATCGAGG-
3
  and the reverse primer 5
 -TTTACTCGAGTCAGACGC-
CATGGTGATACCGGC-3
  (theBamHIandXhoIrestrictionsites
are underlined), cloned into pGEX 6P-1 (GE Healthcare) and
veriﬁed by sequencing.
The resulting construct was transformed into E. coli
BL21(DE3) pLysS cells, which were then grown overnight at
37◦C in 80 ml of Luria–Bertani medium supplemented with
100 μg/ml carbenicillin. This culture was then used to inoculate
8 litres of autoinduction medium [2] with carbenicillin, in which
the cells were grown for 48 h at 25◦C before harvesting by
centrifugation at 3500 g for 30 min. Cells were washed, then
resuspended in 50 ml of 25 mM Tris/HCl (pH 7.5) and 250 mM
NaCl and lysed by passage through a continuous-ﬂow cell
disrupterat207MPa(ConstantSystems).Aftercentrifugationand
ﬁltration,thesolublefractionofthelysatewasincubatedfor2 hat
4◦C with 4 ml of glutathione–Sepharose beads (GE Healthcare),
then washed with lysis buffer. After addition of 400 μgo fG S T -
tagged PreScission protease, the beads were incubated overnight
at 4◦C. Beads were removed, and the ﬁltrate was dialysed into
25 mM Tris/HCl (pH 7.5) before loading on to a 5 ml HiTrap Q
FF column (GE Healthcare) equilibrated in the same buffer. After
washing protein was eluted using a 0–500 mM NaCl gradient.
Fractions containing OgOGA were pooled and concentrated to
<5 ml for gel ﬁltration using a XK26/60 Superdex 75 gel-
ﬁltration column equilibrated in 25 mM Tris/HCl (pH 7.5) and
150 mM NaCl. The resulting fractions containing pure OgOGA
as veriﬁed by SDS/PAGE were pooled and concentrated to
1.9 mg/ml.
OgOGA structure determination
OgOGA was crystallized at 20◦C using sitting-drop vapour
diffusionwithdropsof1μlofproteinsolutionmixedwith1μlof
motherliquorovera60μlreservoirof18%poly(ethyleneglycol)
4000, 100–250 mM MgCl2 and 100 mM Tris/HCl (pH 8.5).
Crystals appeared overnight as hexagonal prisms. Crystals were
cryoprotected using a mixture of 80% mother liquor and
20% ethylene glycol. For the PUGNAc complex structure,
solid PUGNAc was added to a drop containing crystals for
30 min before cryoprotection. For phasing, 0.17 μl of a solution
of 200 mM lead acetate in mother liquor was added to a
drop containing crystals for 1 h before cryoprotection. All data
were collected at the European Synchrotron Radiation Facility
(Grenoble, France) at a temperature of 100 K, and processed
using HKL software [3] (Supplementary Table S1). OgOGA
crystals are of space group C2 with one protein molecule per
asymmetric unit. Data for the PbAc2 derivative were collected
at beamline BM14 with λ = 0.946 Å (peak) and λ = 0.950 Å
(inﬂection point) and processed/scaled to 1.9 Å and 2.0 Å
respectively. Phases were calculated using SHELXC/D/E [4,5]
through the HKL2MAP interface [6], WarpNtrace [7] built 264
of a possible 447 residues. After manual completion using Coot
[8], REFMAC5 [9] and other CCP4 software [10], the resulting
model was used for molecular replacement into the native 2.0
Å dataset. Model building and reﬁnement proceeded as for the
derivative structure and resulted in a ﬁnal model with an Rwork
of 0.186 and an Rfree of 0.222 with good geometry throughout
(Supplementary Table S1). The PUGNAc complex was solved by
molecular replacement with the derivative structure and reﬁned
as above to an Rwork of 0.242 and an Rfree of 0.279 with good
geometry. Both reported structures exhibit two poorly ordered
regions, one comprising several residues directly preceding helix
α4 (modelled in the apo structure), the other covering part of
the α13–α14 loop (lacking in both models). Additionally, the
12 C-terminal residues are disordered in the PUGNAc complex.
Interestingly, the residues lacking from the α13–α14 loop would
not be able to span the distance (31.4 Å, in principle covered
by ﬁve amino acids, i.e. 6.28 Å per amino acid) between the
built amino acids on either side of the gap; it is possible that
the actual connection is between two monomers and the protein
thus forms a (sub)domain-swapped dimer (distance = 13.2 Å,
giving an average of 2.64 Å span per residue). This has not
been modelled as such, as OgOGA is monomeric in solution
(by gel-ﬁltration; results not shown). Alternatively, the distance
betweenthedisorderedendsoftheloopcouldbeexplainedbythe
effects of an unknown proteolytic event. Finally, the termini of
helices α13 and α14 are 29 Å apart, which can easily be covered
by the α13–α14 loop (21 residues, ∼1.3 Å per residue) after a
degree of conformational change.
Ligand co-ordinates and topologies were generated with
PRODRG[11];duringmodelbuilding,itbecameapparentthatthe
ligand electron density covered only the (pseudo)sugar ring and
the rest of the molecule was either disordered or, more likely, had
been hydrolysed. Consistent with the latter hypothesis, the ligand
was modelled as a tetrahydropyran-2-one derivative. Figure 1(B)
of the main text was created using Aline [12], Figures 2(C)–
2(E) of the main text and the surface views in Figure 3(B) of
the main text were rendered using PyMOL (DeLano Scientiﬁc
http://www.pymol.org).
1 These authors contributed equally to this work
2 To whom correspondence should be addressed (email dmfvanaalten@dundee.ac.uk).
Structures have been deposited in the PDB under accession codes 2XSA and 2XSB.
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Table S1 X-ray crystallographic data collection and structure reﬁnement statistics
Values for the highest resolution shell are given in parentheses.
Statistic Apo-OgOGA OgOGA-PUGNAc
Beamline/wavelength (A ˚) ID23-2/0.873 ID14-1/0.934
Resolution (A ˚) 25.00–2.00 (2.03–2.00) 20.00–2.10 (2.17–2.10)
Unit cell a = 84.4 A ˚, b = 95.3 A ˚, c = 60.5 A ˚,
β = 104.0◦
a = 84.6 A ˚, b = 96.3 A ˚, c = 60.0 A ˚,
β = 104.0◦
Number of unique reﬂections 31362 26338
Redundancy 4.4 (4.1) 3.2 (2.9)
Completeness (%) 99.3 (94.3) 98.9 (95.7)
I/σ(I) 33.8 (5.6) 11.3 (2.3)
Rmerge 0.072 (0.291) 0.095 (0.574)
Wilson B (A ˚2) 36.9 41.0
Rwork, Rfree 0.186, 0.222 0.242, 0.279
Average B-factor
Protein (A ˚2) 41.4 37.0
Solvent (A ˚2) 43.6 32.1
Ligand (A ˚2) n/a 39.3
RMSD from ideal geometry: bond lengths (A ˚)/bond angles (◦) 0.014/1.30 0.012/1.30
Ramachandran statistics (most favoured/additionally allowed/generously
allowed/disallowed)
91.8%/7.9%/0.3%/0% 90.8%/9.2%/0%/0%
Table S2 Oligonucleotides used for introducing point mutations in the
coding sequence of hOGA
Oligonucleotide Sequence (5 →3 )
Y69S_fwd GTGGTGGAAGGATTTTCTGGAAGACCTTGGG
Y69S_rev CCCAAGGTCTTCCAGAAAATCCTTCCACCAC
L141S_fwd GATCTCACCTGGATCGGATATCACTTTTTC
L141S_rev GAAAAAGTGATATCCGATCCAGGTGAGATC
L141A_fwd GATCTCACCTGGAGCGGATATCACTTTTTC
L141A_rev GAAAAAGTGATATCCGCTCCAGGTGAGATC
I176L_fwd CTTTGCTTTTTGATGATCTAGACCATAATATGTG
I176L_rev CACATATTATGGTCTAGATCATCAAAAAGCAAAG
S190A_fwd CAAAGAGGTATTCAGTGCTTTTGCTCATGCCCAAG
S190A_rev CTTGGGCATGAGCAAAAGCACTGAATACCTCTTTG
S190Q_fwd CAAAGAGGTATTCAGTCAGTTTGCTCATGCCCAAG
S190Q_rev CTTGGGCATGAGCAAACTGACTGAATACCTCTTTG
T217A_fwd CTTTCCTCTTCTGTCCCGCAGAATACTGTGGCAC
T217A_rev GTGCCACAGTATTCTGCGGGACAGAAGAGGAAAG
E218S_fwd CTCTTCTGTCCCACATCATACTGTGGCACTTTC
E218S_rev GAAAGTGCCACAGTATGATGTGGGACAGAAGAG
F223S_fwd GAATACTGTGGCACTTCCTGTTATCCAAATGTG
F223S_rev CACATTTGGATAACAGGAAGTGCCACAGTATTC
V255G_fwd CAGGTCCCAAAGTTGGTTCTAAAGAAATTCC
V255G_rev GGAATTTCTTTAGAACCAACTTTGGGACCTG
V255T_fwd CAGGTCCCAAAGTTACTTCTAAAGAAATTCC
V255T_rev GGAATTTCTTTAGAAGTAACTTTGGGACCTG
Y286S_fwd CATTCATGCTAATGATTCTGATCAGAAGAGACTG
Y286S_rev CAGTCTCTTCTGATCAGAATCATTAGCATGAATG
D287A_fwd CATGCTAATGATTATGCTCAGAAGAGACTGTTTC
D287A_rev GAAACAGTCTCTTCTGAGCATAATCATTAGCATG
Q288A_fwd GCTAATGATTATGATGCGAAGAGACTGTTTCTGGG
Q288A_rev CCCAGAAACAGTCTCTTCGCATCATAATCATTAGC
K289S_fwd CTAATGATTATGATCAGTCGAGACTGTTTCTGGGCCCG
K289S_rev CGGGCCCAGAAACAGTCTCGACTGATCATAATCATTAG
R290A_fwd GATTATGATCAGAAGGCACTGTTTCTGGGCCCGTAC
R290A_rev GTACGGGCCCAGAAACAGTGCCTTCTGATCATAATC
Y569A_fwd CTATTCTACCTTCCTGCCGAGCATGGACCCAAAG
Y569A_rev CTTTGGGTCCATGCTCGGCAGGAAGGTAGAATAG
W679N_fwd GGAGACCAAGAACCCAATGCCTTTAGAGGTGGTC
W679N_rev GACCACCTCTAAAGGCATTGGGTTCTTGGTCTCC
A680F_fwd GACCAAGAACCCTGGTTCTTTAGAGGTGGTCTAG
A680F_rev CTAGACCACCTCTAAAGAACCAGGGTTCTTGGTC
K289A_fwd CTAATGATTATGATCAGGCGAGACTGTTTCTGGGCCCG
K289A_rev CGGGCCCAGAAACAGTCTCGCCTGATCATAATCATTAG
Figure S1 In vitro O-GlcNAcylation of proteins with OGT generates OGA
substrates
GlcNAcylation reactions on GST (control), TAB1, GST–FoxO1 or GST–CREB. Full-length OGT
was used for GST and CREB, a truncated ( 9) construct for FoxO1 and a GST fusion thereof
(GST– 9) for TAB1. Reactions contained 3.75mM UDP-GlcNAc and recombinant OGT in
50mM Tris/HCl (pH7.5) plus 1mM DTT (dithiothreitol). Enzyme/substrate protein ratios were
1:20, total protein concentration was 0.5mg/ml. The reaction was allowed to proceed for 3 h
at 37◦C. The top panel shows the different constructs of OGT, detected with DM-17 rabbit
hOGT antiserum, the middle panel shows O-GlcNAcylation, as detected with the CTD110.6
antiserum, and the bottom panel shows total protein staining. This was necessary as the TAB1
used in this experiment did not carry a GST tag, but also serves to illustrate the presence
of degradation products in the FoxO1 and CREB samples, some of which appear to bear the
O-GlcNAc modiﬁcation, as seen in the middle panel.
Glycopeptide synthesis
The 2,3,4,6-tetracetyl-O-GlcNAc-Fmoc-Ser derivative was
synthesised according to the published procedure [13]. Solid-
phase peptide synthesis was performed on automated microwave-
assisted peptide synthesizer CEM Liberty on low-load Rink
amide MBHA (methylbenzhydrylamine) resin 100–200 mesh
(Novabiochem) using standard Fmoc chemistry protocols on
0.05 mmol scale. Fmoc deprotection was executed with
20% piperidine-DMF (dimethylformamide) at 70◦Cf o r3m i n .
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Figure S2 OgOGA pH optimum and time-dependent removal of O-GlcNAc
from peptide by OgOGA
(A) Time-dependent removal of O-GlcNAc from peptide by OgOGA. A β-O-GlcNAc-modiﬁed
peptidesubstratewascompletelydeglycosylatedbyOgOGAinthecourseof2h.Reactionswere
performedandanalysedafterincubationat37◦Cfortheindicatedlengthsoftime.Thesynthetic
pentapeptide Ala-His-Ser-(β-O-GlcNAc)-Gly-Ala (molecular mass 785 Da) was progressively
transformedintothedeglycosylatedformwithamolecularmassof582Da.Thepresenceofapeak
at582Dainthecontrolsamplewasmostlikelytobeanartefactoftheionizationprocedure,asthe
glycopeptide sample appeared to be pure and no traces of contaminants were detected by NMR
analysis. (b) pH optimum of OgOGA. Initial rates of hydrolysis of 4MU-GlcNAc were measured
in buffer containing MacIlvaine buffers, ranging from pH4 to pH8, plus 0.1mg/ml BSA, with
substrate concentrations of 200 μM and 0.2nM enzyme in a 50 μl assay volume. After 20min
of incubation at 37◦C, the reaction was stopped by addition of 100 μl of 3M glycine/NaOH
(pH10.3). Product formation was determined ﬂuorimetrically (λex = 360nm/λem = 460nm)
using a FLx800 microplate ﬂuorescence reader (Bio-Tek). The highest value measured was
arbitrarily set to 100%. OgOGA possesses a pH optimum of 7.4–7.6, comparable with hOGA
(pH6.5), and compatible with an intracellular location.
Coupling of Fmoc amino acids (four equivalents) was mediated
by PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexaﬂuorophosphate)(fourequivalents)inthepresenceofDIPEA
(N,N-di-isopropylethylamine) (four equivalents) in DMF/N-
methyl-2-pyrrolidone 4:1 at 70◦C for 10 min except for serine
and histidine that were coupled at 50◦C to prevent epimerization.
Acetylation was achieved after removal of Fmoc protection
from the N-terminus with 20% acetic anhydride in pyridine
at 70◦C for 5 min. After completion of the synthesis, the
resin was collected in a 15 ml disposable PP (polypropylene)
reservoir (Biotage) ﬁtted with a PP fritted disk and PTFE
[poly(tetraﬂuoroethylene)] stopcock. The resin was successively
washed with DCM (dichloromethane) (3×5 ml) and methanol
(3×5 ml). The acetate protections from the sugar residue were
then removed by treatment with a solution of hydrazine hydrate
in methanol 1:4 (2 ml) for 1 h at room temperature (23◦C). The
reagent was ﬁltered off and the treatment was repeated twice
for 30 min with the same amount of fresh reagent. Finally, the
resin was successively washed with methanol (3×5m l ) a n d
DCM (3×5 ml). The resin was then treated with a cleavage
cocktail (2 ml) made of TFA (92%), water (2.5%), phenol
(2.5%), DODT (3,6-dioxa-1,8-octanedithiol) (2.5%)a n dT I S
(tri-isopropylsilane) (1%) for 2 h at room temperature. The
cleavage cocktail was drained off and collected, and the resin
was washed with neat TFA (triﬂuoroacetic acid) (2×1m l ) .T h e
combined ﬁltrate was concentrated in vacuo to approx. 1 ml.
The peptides were precipitated with ice-cold diethyl ether (35 ml)
and recovered by centrifugation at 3000 g for 15 min. The pellet
waswashedtwicewithfreshdiethylether(35 ml),thenblowdried
with argon, dissolved in water/acetic acid/acetonitrile (3:1:0.5,
by vol.) (5 ml) and freeze-dried. The crude glycopeptides were
puriﬁed by reverse-phase HPLC on a 21.1×100 Luna C18
(2) column (Phenomenex) using a linear gradient of 5–95%
acetonitrile in water (0.1% ammonia). UV detection was at
214 nm. Appropriate fractions were collected and freeze-dried
to afford the target glycopeptides in 50–70% yield based on the
resin-loading capacity.
The structural homogeneity of the glycopeptides was veriﬁed
by high-resolution mass spectra taken using a Bruker micro-TOF
(time-of-ﬂight) instrument in the direct injection mode.
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Figure S3 Sequence alignment of OGAs
Structure-based alignment of hOGA, OgOGA, CpNagJ and BtOGA, covering the catalytic and stalk domains. Black/grey boxes indicate sequence conservation, further coloured boxes indicate
conservation between hOGA and OgOGA (red), hOGA and CpNagJ (blue), hOGA and BtOGA (yellow). Bt, Bacillus thetaiotamicron.
c   The Authors Journal compilation c   2010 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Human OGA binds substrates in a conserved peptide recognition groove
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